Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704.TWO)

TWD 21.75

(1.4%)

Market Cap (In TWD)

2.08 Billion

Revenue (In TWD)

141.17 Million

Net Income (In TWD)

-88.08 Million

Avg. Volume

70.88 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
23.55-40.4
PE
-19.59
EPS
-1.11
Beta Value
0.0
ISIN
TW0006704000
CUSIP
-
CIK
-
Shares
95949320.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mingxi Zhuang
Employee Count
-
Website
https://www.gwoxi.com.tw
Ipo Date
2023-04-26
Details
Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell medicines for patients with unmet medical needs. The company's products under development include GXHPC1, a novel autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, a novel autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. It is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the treatment of osteoarthritis; and GXIPC1, an allogeneic adipose-derived stem cells therapy in phase I clinical trials for use in the treatment of diabetes. The company was founded in 2011 and is based in Zhubei, Taiwan.